Trial Search Results

CemiplimAb Survivorship Epidemiology

The objectives of the study are:

- To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced CSCC in real-world clinical settings

- To evaluate the safety of cemiplimab based on incidence of treatment related immune-related adverse events (irAEs), infusion related reactions (IRRs), and treatment related serious adverse reactions (SARs) in patients with advanced CSCC receiving cemiplimab treatment in real world clinical settings

- To describe patient experience, including patient reported quality of life (QOL) and functional status, and clinician reported performance status in a real-world setting for patients with CSCC

- To describe baseline characteristics that could potentially be associated with health-related outcomes for patients with Cutaneous squamous cell carcinoma (CSCC) undergoing treatment with cemiplimab

- To describe patients who receive cemiplimab as treatment for CSCC in a real-world setting

- To describe real-world use patterns of cemiplimab for CSCC

- To investigate the long-term effects and effectiveness of cemiplimab in CSCC patients

- To describe the effectiveness of cemiplimab in immunosuppressed and immunocompetent patients with advanced CSCC, regardless of etiology, per available data

- To describe the effectiveness of cemiplimab after prior exposure to radiation therapy for CSCC per available data

- To describe the effectiveness of cemiplimab as a first-line (1L) or later systemic treatment in patients with advanced CSCC, regardless of etiology, per available data

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Regeneron Pharmaceuticals

Stanford Investigator(s):


  • Drug: cemiplimab


Key Inclusion Criteria:

   - Eligible for treatment with and prescribed cemiplimab for advanced CSCC in accordance
   with approved prescribing information as described in the protocol

Key Exclusion Criteria:

   - Receiving cemiplimab for an indication other than CSCC

   - Any condition that, in the opinion of the investigator, may interfere with patient's
   ability to participate in the study

   - Patients concurrently participating in any study including administration of any
   investigational drug (including cemiplimab) or procedure (including survival follow

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Julie Nguyen
Not Recruiting